Cannara Biotech Inc. (LOVE:TSX; LOVFF:OTCQX; BCB0:FSE) began trading on the Toronto Stock Exchange at the open on March 2, 2026. The listing included 98,782,148 common shares issued and outstanding, with an additional 14,817,322 shares reserved for issuance. The shares trade under the symbol LOVE in Canadian dollars with Cusip No. 13765U 20 0.
According to the Toronto Stock Exchange, Cannara Biotech is a vertically integrated producer of cannabis and cannabis-derivative products for the Canadian markets. The company's transfer agent and registrar is Computershare Investor Services Inc., with principal offices in Toronto and Vancouver. Cannara Biotech's fiscal year-end is August 31, and the temporary market-maker is Independent Trading Group (ITG) Inc.
Cannara Biotech had previously been listed on the TSX Venture Exchange since April 8, 2021, under the symbol LOVE. The company was delisted from the TSX Venture Exchange on March 2, 2026, concurrent with the start of trading on the Toronto Stock Exchange.
Expanding Legal Markets and Industry Fragmentation in the Cannabis Sector
According to a March 3 report from ResearchAndMarkets.com, the global cannabis industry had grown into a large and diverse market spanning multiple segments, including legal retail sales, analytical testing services, extraction technologies, and cannabis-derived pharmaceuticals. The report stated that "the global market for cannabis was valued at from US$45.6 billion in 2025 and is projected to reach US$79.3 billion by the end of 2030, at a compound annual growth rate (CAGR) of 11.7% during the forecast period of 2025 to 2030." It added that key opportunities within the sector included "growth in cannabis-derived pharmaceuticals, expansion of legal retail sales for medicinal and adult use, and demand for analytical and extraction services."
The same March 3 report described the legal cannabis landscape as highly competitive, noting that "the competitive landscape of the legal retail cannabis industry is diverse and highly fragmented." The report also identified several industry drivers and challenges affecting the sector, including regulatory expansion and legalization, product innovation, supply chain considerations, and pricing pressure related to cannabis oversupply.
A separate March 3 news report by Liam Bridgeman discussed ongoing legislative developments related to retail cannabis markets in the United States. The report stated that legislation advancing through Virginia's House and Senate would establish a framework for an adult-use retail cannabis market in the state after several years of discussion. According to Delegate Paul Krizek of Fairfax, the current situation reflected a large existing market operating outside regulated channels. Krizek said that cannabis in the Commonwealth represented "a $5 Billion unregulated market."
Advocacy groups also commented on the transition from illicit sales to regulated retail channels. JM Pedini, development director for the National Organization for the Reform of Marijuana Laws, stated that legalization would move cannabis sales into regulated environments. Pedini said, "Virginia's Marijuana market is already here and is very well established; however, what legalization does is allows the state to take marijuana out of the corner store, off street corner, and instead place it behind an age-verified counter where it can only be sold to adults 21 or older."
The report added that proposed legislation included regulatory provisions for retail licensing and oversight, including a limit of 350 retail licenses statewide. Local governments would retain zoning authority over cannabis retailers and would receive a portion of sales tax revenue generated by the market.
Additional commentary on sector dynamics appeared in a March 8 weekly roundup from Market Exclusive covering developments in the cannabis industry. The publication wrote that the sector was undergoing structural changes and stated that "the cannabis industry is consolidating in real time." The roundup noted that consolidation activity, financial restructuring, and shifts in strategy were occurring across the sector as companies adjusted to evolving market conditions and regulatory frameworks.
'Best-in-Class EBITDA Margins of 29%': Atrium Research Coverage on Cannara
In a March 5 research report, Atrium Research analyst Nicholas Cortellucci provided coverage on Cannara Biotech Inc. with a BUY rating and a CA$3.00 per share target price. The report stated that the target price implied "63% upside from the current share price of CA$1.84."
Cortellucci wrote in the March 5 report that the firm's coverage initiation cited Cannara's operational performance and market positioning, noting the company's "dominant position in Quebec's new vape category" and "best-in-class EBITDA margins of 29%." The report also referenced the company's Valleyfield facility expansion potential, stating that the site represented "a capital-efficient expansion path at its Valleyfield facility that could unlock 100,000 kg of annual production capacity by FY30."
The report described Cannara's financial performance and profitability metrics, stating that "Cannara has posted 19 consecutive quarters of positive adjusted EBITDA and 13 consecutive quarters of positive operating cash flow." It also reported that in the company's most recent quarter, "gross margins reached 45% and adjusted EBITDA margins expanded to 29%."
Atrium Research also referenced Cannara's financial results, writing that in the quarter ending November 30, 2025, the company "reported record net revenue of CA$30.1M, up 20% year-over-year, with gross profit before fair value adjustments of CA$13.5M (45% margin) and adjusted EBITDA of CA$8.8M (29% margin)." The report further stated that for fiscal year 2025, Cannara "delivered net revenue of CA$107.3M (up 31%), adjusted EBITDA of CA$28.1M, and net income of CA$13.1M."
Operations, Facilities, and Capacity Developments
Cannara Biotech operates cannabis cultivation and processing infrastructure in Quebec. Cannara's investor presentation reports that the Valleyfield facility measures approximately 1,033,506 square feet on a site of 3,000,000 square feet and includes 24 independent growing zones, each measuring 25,000 square feet. The facility was acquired in 2021 for $27 million and is described as one of the largest indoor cannabis cultivation facilities in Canada. Twelve growing zones have been activated at the site, including two zones that were activated in April and June 2025. According to the company's investor materials, these activated zones support more than 100,000 plants under cultivation and generate approximately 45,000 kilograms of production per year.
The company stated that the Valleyfield facility provides the ability to expand output capacity to 100,000 kilograms annually. As part of planned infrastructure development, Cannara outlined a first phase build-out of a processing center at Valleyfield intended to dry, trim, and process additional cannabis. The estimated capital expenditure for this first phase is approximately CA$10 million and is intended to activate post-harvest capacity for an additional 12 growing zones.
Cannara also operates a facility in Farnham, Quebec, measuring approximately 605,000 square feet, including 190,000 square feet dedicated to cannabis operations. The Farnham site includes 11 indoor grow rooms totaling 22,000 square feet dedicated to cultivation, as well as post-harvest, packaging, and cannabis processing rooms. The facility also includes a solventless hash lab and a pre-roll manufacturing center.
Streetwise Ownership Overview*
Cannara Biotech Inc. (LOVE:TSX;LOVFF:OTCQX;BCB0:FSE)
The Farnham facility houses a research and development operation focused on pheno-hunting, tissue culture, and analytical testing. The site produces approximately 5,000 kilograms in annual cultivation capacity. The company stated that unoccupied space at the facility is leased to non-cannabis tenants and generates more than CA$3.8 million in annual rental revenue.
Cannara reported that its current annualized cannabis production is approximately 50,000 kilograms. The company outlined a capital expenditure plan of CA$30 million over three years aimed at reaching 100,000 kilograms of annualized production capacity. As part of that plan, Cannara described a fiscal 2026 post-processing expansion intended to activate three additional rooms in fiscal 2027, adding approximately 15,000 kilograms of production capacity for about CA$3 million in capital expenditures.
The company also described a modular activation approach for its cultivation infrastructure. Existing grow room shells at the Valleyfield facility can be activated in stages, with room activations targeted at a cadence of two to three rooms per year. The company indicated that incremental capital expenditures are associated with room activation rather than new construction and that automation and quality assurance systems are used to maintain operational consistency as production volume increases.
Ownership and Share Structure1
Insiders own approximately 27.32% of Cannara Biotech, with Zohar Krivorot holding the most at 25.83%. 24.09% is held by strategic entity Olymbec Investments Inc. Institutions hold 0.22%. The rest is retail.
The company has 98.78 million outstanding shares, a market cap of US$136.16 million. Its 52-week range is CA$1.06 - CA$2.07 per share.
| Want to be the first to know about interesting Nutraceuticals and Biotechnology / Pharmaceuticals investment ideas? Sign up to receive the FREE Streetwise Reports' newsletter. | Subscribe |
Important Disclosures:
- James Guttman wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee.
- This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.
- This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.
For additional disclosures, please click here.
1. Ownership and Share Structure Information
The information listed above was updated on the date this article was published and was compiled from information from the company and various other data providers.
